Emmaus Life Sciences Reports $2.4 Million Revenue and $2.3 Million Net Loss in Q1 2025

Emmaus Life Sciences, Inc. reported a net revenue of $2.4 million for the first quarter of 2025, a decrease of 4% from $2.5 million in the same period of 2024. The decline in revenue is attributed to reduced sales in the U.S. market, primarily due to competition from a newly introduced generic version of L-Glutamine oral powder by ANI Pharmaceuticals, which began affecting sales in mid-2024. Despite this, the company noted an increase in sales within the Middle East and North Africa (MENA) region, where Endari® has received marketing authorizations in several countries, including the United Arab Emirates, Qatar, Kuwait, and Oman.

Emmaus reported a net loss of $2.3 million for the three months ended March 31, 2025, a significant improvement compared to a net loss of $4.3 million for the same period in 2024. This reduction in loss was primarily due to decreased operating expenses, including a 67% reduction in selling expenses, which fell to $0.6 million from $1.9 million year-over-year. General and administrative expenses also decreased by 18% to $2.3 million, reflecting cost-cutting measures, including a reduction in headcount.

The company’s total assets as of March 31, 2025, included cash and cash equivalents of $1.3 million, down from $1.7 million at the end of the previous fiscal year. Emmaus continues to face significant financial challenges, with a working capital deficit of $59.3 million and an accumulated deficit of $264.9 million. The company indicated that it will need to raise additional capital through loans, equity financing, or strategic partnerships to meet its operational and debt obligations.

Operationally, Emmaus has made strategic adjustments, including a reduction in its internal sales team and the termination of its Chief Commercialization Officer in late 2024. The company is also navigating ongoing legal challenges, including a recent court ruling in Dubai that awarded a former employee approximately $483,500, which the company is considering appealing. The company’s future outlook remains uncertain, with substantial doubt about its ability to continue as a going concern over the next 12 months without securing additional funding.

Looking ahead, Emmaus plans to focus on increasing sales of Endari® in the MENA region while addressing the competitive pressures in the U.S. market. The company is also exploring options for restructuring its existing debt and enhancing its operational efficiencies to improve its financial position.